22,700 Shares in Takeda Pharmaceutical Co. $TAK Acquired by Nomura Holdings Inc.

Key Points

• Nomura Holdings Inc. has made a new investment in Takeda Pharmaceutical Co., acquiring 22,700 shares valued at approximately $338,000.
• Takeda's recent earnings report showed an EPS of $0.52, exceeding analyst expectations, but fell short on revenue with $7.45 billion reported against a consensus of $7.96 billion.
• Institutional investors collectively own 9.17% of Takeda's stock, indicating significant interest from larger financial entities.

Nomura Holdings Inc. purchased a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 22,700 shares of the company's stock, valued at approximately $338,000.

A number of other hedge funds have also made changes to their positions in TAK. Soleus Capital Management L.P. raised its holdings in shares of Takeda Pharmaceutical by 136.0% during the fourth quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock valued at $15,623,000 after acquiring an additional 680,000 shares during the last quarter. Toronto Dominion Bank acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $6,760,000. BNP Paribas Financial Markets raised its holdings in shares of Takeda Pharmaceutical by 15,449.0% during the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock valued at $6,629,000 after acquiring an additional 497,457 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $5,915,000. Finally, ABC Arbitrage SA acquired a new position in shares of Takeda Pharmaceutical during the first quarter valued at approximately $4,994,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold".

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK traded up $0.01 during midday trading on Tuesday, hitting $15.28. The company had a trading volume of 3,353,014 shares, compared to its average volume of 2,604,038. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The stock has a market cap of $48.62 billion, a price-to-earnings ratio of 50.93 and a beta of 0.22. The business's 50-day simple moving average is $14.82 and its 200-day simple moving average is $14.81.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion during the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, research analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.